

**NNATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

**STA Dapagliflozin for treating chronic kidney disease
[ID3866]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?
N/A

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?
Patient and clinical expert submissions highlighted that CKD mostly affects people from black, Asian, and minority ethnic groups and lower socioeconomic backgrounds and people from these groups are also more likely to have CKD that progresses quicker to kidney failure and die earlier. However, the committee noted that issues related to differences in prevalence or incidence of a disease cannot be addressed in a technology appraisal. It did not consider these to be equality issues that could be resolved by this appraisal.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?
No

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
N/A

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?
Yes, section 3.22 of ACD

Approved by Associate Director (name): ...Linda Landells.....

Date: 27 October 2021

Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

A potential equality issue was raised regarding use of ACE inhibitors or ARBs differing by ethnicity and socioeconomic status. However, the committee did not consider these to be equality issues that could be resolved by this appraisal.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

N/A

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
Yes – section 3.22

Approved by Associate Director (name):Linda Landells.....

Date: 13 January 2022